Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLT94F)

• Drug Name: VLS-101 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DMLT94F

Molecule-Related Drug Atlas

Drug(s) Targeting Neurotrophic tyrosine kinase ROR1 (ROR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zilovertamab vedotin	DM1MZAQ	Diffuse large B-cell lymphoma	2A81	Phase 2/3	[3]
Cirmtuzumab	DM98RW0	Chronic lymphocytic leukaemia	2A82.0	Phase 2	[4]
Zilovertamab	DMMEJ6K	Mantle cell lymphoma	2A85.5	Phase 2	[5]
NBE-002	DMTAODR	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[6]
ROR1R-CAR-T Cell	DMIAK9P	leukaemia	2A60-2B33	Phase 1	[7]
ROR1 CAR-specific Autologous T-Lymphocytes	DM5EUIY	Acute lymphoblastic leukaemia	2A85	Phase 1	[8]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Neurotrophic tyrosine kinase ROR1 (ROR1)	TTDEJAU	ROR1_HUMAN	Not Available	[2]

References

• [1] ClinicalTrials.gov (NCT04504916) A Study of VLS-101 in Patients With Solid Tumors. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of VelosBio.
• [3] ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models. Blood. 2021 Jun 17;137(24):3365-3377.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] The Anti-ROR1 Monoclonal Antibody Zilovertamab Inhibits the Proliferation of Ovarian and Endometrial Cancer Cells. Pharmaceutics. 2022 Apr 11;14(4):837.
• [6] Clinical pipeline report, company report or official report of NBE-Therapeutics.
• [7] ClinicalTrials.gov (NCT02194374) Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)
• [8] ClinicalTrials.gov (NCT02706392) Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies